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Abstract   Software traceability is central to medical device software develop-
ment and essential for regulatory approval. In order to comply with the regulatory 
requirements of the medical device industry it is essential to have clear linkages 
and traceability from requirements - including risks - through the different stages 
of the software development and maintenance lifecycles.  The regulatory bodies 
request that medical device software development organizations clearly demon-
strate how they follow a software development lifecycle without mandating a par-
ticular lifecycle. However, due to the traceability requirements of the industry 
most medical device companies adopt the V-model. Within this chapter we will 
discuss the importance of traceability to medical device software development, the 
current state of practice within the industry in relation to traceability and how we 
feel that traceability could be improved within the industry. The chapter also de-
scribes the development and implementation of a medical device traceability soft-
ware process assessment method (Med-Trace) in two medical device software de-
velopment organizations. We include these two case studies as one involved a 
medical device SME based in Ireland and the other a medical device SME based 
in the UK as we want to illustrate that Med-Trace can be applied within different 
countries. 
Keywords: Medical device standards, Medical device software traceability, Medi-
cal device software process assessment and improvement 
X.1 Introduction 
Software is becoming an increasingly important component of medical devices, as 
it enables often complex functional changes to be implemented without having to 
change the hardware [1]. With increasing demands for greater functionally within 
medical devices, the complexity of medical device software development also in-
creases [2]. This therefore places increased demands for appropriate traceability 
and risk management processes and tools.  
2  
Due to the safety-critical nature of medical device software it is important that 
highly effective software development practices are in place within medical device 
companies. Medical device companies must comply with the regulatory require-
ments of the countries in which they wish to sell their devices [3]. To tackle these 
issues, governments have put in place regulatory bodies whose role is to define 
regulatory systems for medical devices and to ensure that only safe medical devic-
es are placed on the market [4]. Although guidance exists from regulatory bodies 
on what software activities must be performed, no specific method for performing 
these activities is outlined or enforced [5].  
To this end, in the USA, the Food and Drug Administration (FDA) Center for 
Devices and Radiological Health (CDRH) has published guidance papers which 
include risk-based activities to be performed during software validation [6], pre-
market submission [7] and when using off-the-shelf software in a medical device 
[8].  Although the CDRH guidance documents provide information on which 
software activities should be performed, they do not enforce any specific method 
for performing these activities. The obvious implication of this is that medical de-
vice manufacturers could fail to comply with the expected requirements. 
Therefore, within the medical device industry a decision was made to recognize 
ISO/IEC 12207:1995 [9] (a general software engineering lifecycle process stand-
ard) as being suitable for general medical device software development.  Howev-
er, the Association for the Advancement of Medical Instrumentation (AAMI) 
software committee carefully reviewed ISO/IEC 12207:1995 and decided that, due 
to a number of shortfalls, it was necessary to create a new standard specifically for 
medical device software development. The AAMI used ISO/IEC 12207:1995 as 
the foundation for their new standard “AAMI SW68, Medical device software – 
Software lifecycle processes” [12]. In 2006, a new standard AAMI/IEC 62304 
[10] was released that was based on the AAMI SW68 standard. 
In 1993, the Council of the European Communities published the Council Di-
rective 93/42/EEC (1993) [11], the “Medical Device Directive” (MDD), on medi-
cal devices. The MDD is intended to ensure the safety of medical devices placed 
on the market in the European Union, and has the backing of national legislation 
in member states.  Amendments to this directive occurred via Directives 
2000/70/EC (2000) [12], 2001/104/EC (2001) [13], 2003/32/EC (2003) [14], and 
2007/47/EC (2007) [15].    
Whenever we mention medical device guidelines within this chapter we refer 
to the following medical device standards and guidelines: IEC 62304, FDA, the 
MDD, ISO 14971 [16], EN 60601-4 [17], TIR 32 [18], IEC 80002-1[19], IEC 
62366 [20], GAMP 5 [21], IEC/TR 61508 [22], ISO 13485[23] and IEC 60812 
[24]. 
In this context, we embarked on a study of Software Traceability, which is crit-
ical to the requirements and safety aspects of software for medical devices. Within 
this chapter we include the following sections:  
2. Requirements for traceability in the context of software development     
for medical devices; 
3. The development of an software traceability process assessment meth-
od (Med-Trace) for determining the capability of a medical device soft-
3 
ware development organization to perform regulatory compliant and ef-
fective traceability; 
4. Implementation of Med-Trace within two medical device software de-
velopment organizations; 
5. How each of the two assessed organizations plan to improve traceabil-
ity; 
6. Challenges the medical device software industry is facing in terms of 
implementing traceability; 
7. Foundation for further research in this area and how Med-Trace may 
be rolled out to assist organizations. 
X.2 Requirements for medical device software traceability 
In order to understand the requirements for traceability in the context of medical 
device software development we conducted a literature review of generic practices 
for software traceability and in particular a review of the medical device standards 
requirements for traceability.  
X.2.1 Traceability Literature Review   
The literature review was undertaken in three stages and focused on: 
 Generic software development and traceability; 
 Safety-critical software development and traceability; 
 Medical device software traceability requirements.  
X.2.2 Traceability for Generic Software Development 
“Requirements traceability refers to the ability to describe and follow the life of a 
requirement in both a forwards and backwards direction - i.e. from its origins, 
through its development and specification, to its subsequent deployment and use, 
and through periods of on-going refinement and iteration in any of these phases” 
[25]. An important focus of requirements traceability is identifying how high level 
requirements are transformed into low level requirements and how these are sub-
sequently implemented in the software product.  
Initially requirements traceability was utilized as an aid in tracing requirements 
from customer/stakeholder needs to implementation and final verification before 
delivering the product to the customer. The role traceability plays has expanded 
and it has become an important tool in the software development activities of pro-
ject management, change management, and defect management [26]. This is par-
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ticularly relevant as software development is increasingly globally distributed 
across multiple teams and sites [27], [28].  It is therefore essential to have an ef-
fective traceability process in place as it provides an essential support for develop-
ing high quality software systems [29].  
When considering generic software development, two of the most popular 
process assessment and improvement frameworks are the Capability Maturity 
Model
®
  Integration (CMMI
®
) [30] and  ISO/IEC 15504-5:2006 [31], [32].  Both 
recognize the importance traceability plays and incorporate it in their respective 
models.  Each model was reviewed in detail with regard to the requirement for ef-
fective traceability and how this was addressed. 
X.2.3 Traceability for Safety-Critical Development 
Software products are increasingly being deployed in complex, potentially dan-
gerous products such as military systems, cars, aircrafts and medical devices. 
Software products for these areas can be critical because failure can result in loss 
of life, significant environmental damage, or major financial loss [33].  
Traceability is especially vital for critical systems which must satisfy a range of 
functional and non-functional requirements, including safety, reliability and avail-
ability [34].  
Within the safety-critical software arena, different standards/certifications are 
available for different industries. These include DO-178B [35]  for the Aerospace 
industry, with Automotive SPICE [36] and ISO 26262 [37] being required in the 
Automotive industry.  IEC 60880 [38] describes the European standards for certi-
fication of nuclear power generating software and IEC/TR 61508 [22]  describes a 
general-purpose hierarchy of safety-critical development methodologies that have 
been applied to a variety of domains ranging from medical instrumentation to 
electronic switching of passenger railways. Requirements traceability is an impor-
tant clause in all the above mentioned standards/certifications.  
In addition to the software development lifecycle, a software safety lifecycle 
has also to be implemented for safety-critical systems.  It is crucial to maintain 
traceability between the software safety requirements, the decisions taken during 
design, and their actual implementation in the code. This is a complex task and 
needs to be performed whilst the system is being developed and not after the de-
velopment has finished [39].    
X.2.4 Medical Device Software Traceability Requirements    
A detailed review was undertaken of the medical device guidelines with regard to 
traceability. A key point to emerge from this study is that while requirements 
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traceability is essentially part of risk management, hazard traceability is of equal 
importance in medical device software development. The most relevant findings 
regarding traceability are presented here in summary. 
X.2.4.1 ANSI/AAMI/IEC 62304:2006  
In 2006, ANSI/AAMI/IEC 62304:2006 (Medical Device Software – Software Life 
Cycle Processes) was released.   Traceability plays a key role in this standard and 
is defined as the “Degree to which a relationship can be established between two 
or more products of the development process” [10]. It is specifically addressed in 
the following sections of the standard:  Section 5.1 states that “the manufacturer 
shall establish a software development plan for the development activity”. This 
plan shall address "Traceability between system requirements, software require-
ments, software system test, and risk control measures implemented in the soft-
ware". Section 5.2 specifies that “the manufacturer shall verify and document that 
the software requirements are traceable to the system requirements or other 
source.” Section 5.7 states that “the manufacturers shall verify that the software 
system test procedures trace to the software requirements”. In section 7.3 Verifica-
tion of Risk Control Measures the standard specifies that “the Manufacturer shall 
document traceability of software hazards as appropriate: From the hazardous 
situation to the software item. From the software item to the specific software 
cause. From the software cause to the risk control measure and from the risk con-
trol measure to the verification of the risk control measure”  
As part of the Configuration Management Process in section 8 the standard 
specifies that “the manufacturer shall create an audit trail whereby each change 
request, problem reports and approval of change request can be traced. 
 Traceability is also addressed in B.6 Software Maintenance Process which 
states “It is especially important to verify through trace or regression analysis that 
the risk control measures built into the device are not adversely changed or modi-
fied by the software change that is being implemented as part of the software 
maintenance activity”.  
X.2.4.2 Medical Device Directive and Amendments 
The European Medical Device Directive (MDD) [14] mentions traceability twice, 
but only in relation to the calibration of test equipment: In 2007, Directive 
2007/47/EC added the following amendment to section 8 of the MDD: “For de-
vices which incorporate software or which are medical software in themselves, the 
software must be validated according to the state of the art taking into account the 
principles of the development lifecycle, risk management, validation and verifica-
tion”[15].  It is in this context that effective software requirements and risk man-
agement traceability are essential to achieve state of the art validation. 
6  
X.2.4.3 General Principles of Software Validation   
The US FDA CDRH General Principles of Software Validation; Final Guidance 
for Industry and FDA Staff  document [6] provides guidance on validation and 
traceability in medical device software development.  The scope of the document 
outlines that traceability is an important activity that provides support to achieve a 
final conclusion that software is validated. Under section 3.1.2 it states: “the vali-
dation of software typically includes evidence that all software requirements have 
been implemented correctly and completely and are traceable to system require-
ments”.  In section 3.2 it specifies that “software validation includes confirmation 
of conformance to all software specifications and confirmation that all software 
requirements are traceable to the system specifications”. The document goes on to 
outline in section 5 that traceability is key across almost all of the software devel-
opment processes and especially in relation to the requirements, design, construc-
tion and test processes. 
X.2.4.3 Premarket Submissions for Software Contained in Medical Devices 
The FDA CDRH  document Guidance for the Content of Premarket Submissions 
for Software Contained in Medical Devices [7] provides information to industry 
regarding the documentation to include in premarket submissions for software de-
vices, including standalone software applications and hardware-based devices that 
incorporate software. In this document traceability analysis is defined as linking 
together the product design requirements, design specifications, and testing re-
quirements. It also provides a means of tying together identified hazards with the 
implementation and testing of the mitigations. It also states that traceability analy-
sis should be included as part of the premarket submission for Moderate and Ma-
jor level of concern medical devices.  
X.2.4.4 Off-The-Shelf Software Use in Medical Devices  
The FDA CDRH Guidance for Industry, FDA Reviewers and Compliance on Off-
The-Shelf Software Use in Medical Devices [8] document was developed to ad-
dress the many questions asked by medical device manufacturers regarding what 
they need to provide in a pre-market submission to the FDA when they adopt Off-
The-Shelf (OTS) software. With regard to traceability it states:  “The introduction 
of new or modified OTS components to a product baseline may impact the safety 
of the product. Therefore a safety impact assessment of the medical device must 
be performed and the associated hazards documented in a Failure Modes and Ef-
fects Analysis (FMEA) table. Each hazard’s consequence should be provided and 
expressed qualitatively; e.g., major, moderate, or minor. Traceability between 
these identified hazards, their design requirements, and test reports must be pro-
vided”. 
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X.2.4.5 ISO 14971:2007 
ISO 14971:2007 (Medical devices - Application of risk management to medical 
devices) [16] is the de-facto standard on risk management for medical devices. 
The FDA recognize the standard [6] and agree compliance with it as acceptable 
for pre-market submissions in the US [7].  In the EU, conformance with the stan-
dard is also acceptable for meeting the requirements of the medical device direc-
tives. In section A.2.3.5 the standard defines the risk management file as: “Where 
the manufacturer can locate or find the locations of all the records and other 
documents applicable to risk management. This facilitates the risk management 
process and enables more efficient auditing to the standard. Traceability is neces-
sary to demonstrate that the risk management process has been applied to each 
identified hazard.”  
X.2.4.6 IEC/TR 80002-1:2009 
IEC/TR 80002-1:2009 (Medical Device Software – Part 1: Guidance on the ap-
plication of ISO 14971 to medical device software) [19]. Though this technical re-
port does not add to, or otherwise change, the requirements of ISO 14971:2007, it 
does provide direction on how the standard can be implemented specifically for 
medical device software. The technical report states: “The software process should 
set up a system that makes traceability possible, starting from the software-related 
hazards and the software risk control measures and tracing their implementation to 
the corresponding safety-related software requirements and the software items that 
satisfy those requirements. All of these should be traceable to their verification”. 
X.2.4.7 ISO 13485:2003 
ISO 13485:2003 (Medical devices - Quality management systems – Requirement 
for regulatory purposes). The standard specifies requirements for a quality man-
agement system that can be used by an organization for the design and develop-
ment, production, installation and servicing of medical devices, and the design, 
development, and provision of related services  [23]. With reference to traceabil-
ity, the standard states in section 7.5.3.2.1: “The organization shall establish 
documented procedures for traceability. Such procedures shall define the extent of 
product traceability and the records required”.  It goes on in section 7.5.3.2.2 with 
reference to “Particular requirements for active implantable medical devices and 
implantable medical devices” to state: “In defining the records required for trace-
ability, the organization shall include records of all components, materials and 
work environment conditions, if these could cause the medical device not to sat-
isfy its specified requirements. The organization shall require that its agents or dis-
tributors maintain records of the distribution of medical devices to allow traceabil-
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ity and that such records are available for inspection. Records of the name and ad-
dress of the shipping package consignee shall be maintained.” 
X.2.2.8 Traceability for Medical Device software development 
Software development for medical devices can be a difficult and complex endeav-
our compared to other domains. Safety is a key area which must be successfully 
addressed given the potential for harm that defective medical device software can 
cause. An analysis of medical device recalls by the FDA in 1996 [40] found that 
software was increasingly responsible for product recalls: In 1996, 10% of product 
recalls were caused by software-related issues. The standards and guidelines cre-
ated to overcome this have already been discussed, but problems still persist.  In 
the period the 1
st
 November 2009 to 1
st
 November 2010 the FDA recorded 78 
medical device recalls and state software as the cause [41].  
Our literature review highlighted there was a limited amount of published ma-
terial regarding implementation challenges and advances in the field of traceability 
in medical device software.  This was in contrast to other sectors in the same con-
text e.g., automotive and aerospace software development.  Another important as-
pect to emerge from our literature review was that while there is a requirement to 
address traceability, and undertake traceability analysis, there is limited guidance 
available to help implement traceability effectively in organizations.  This finding 
is in line with a review of guidance for all aspects of medical device software de-
velopment which took place in 2009 [42]. 
X.3 Development of the Med-Trace Assessment Method  
One of the main aims of the Regulated Software Research Group in Dundalk Insti-
tute of Technology is to support the growth of a medical device software devel-
opment industry within Ireland. Therefore, as traceability is central to the devel-
opment of regulatory compliant software development we decided to develop an 
assessment method specifically to assist companies to adhere to the traceability 
aspects of the medical device software standards.  
The Adept method [43] was previously developed to provide a lightweight as-
sessment of software processes from CMMI
®
 and ISO/IEC 15504-5 and was not 
domain specific. The Adept method provides an organization with a choice of 12 
process areas that may be assessed using Adept. However, based upon previous 
research four of these process areas are considered to be important to the success 
of any software development company and these processes are therefore manda-
tory - Requirements Management, Configuration Management, Project Planning, 
Project Monitoring & Control.  Therefore, the organization only can select 2 of the 
process areas to be assessed from the remaining 8 process areas. Adept consists of 
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eight stages, the main stage involves an assessment team conducting process area 
interviews for each of the 6 selected process areas with appropriate members of 
the assessed organization. Based upon these interviews a findings report consist-
ing of a set of strengths, issues and recommendations as to how to address the 
highlighted issues is produced.    
Med-Trace is a new lightweight assessment method that provides a means of 
assessing the capability of an organization in relation to medical device software 
traceability. Med-Trace is based upon Adept but whereas Adept relates to generic 
software development processes Med-Trace is specific to the traceability process 
with medical device software development organizations. Med-Trace enables 
these software development organizations to gain an appreciation of the funda-
mental traceability best practices based on the software engineering traceability 
literature, software engineering process models (CMMI
®
, ISO/IEC 15504-5), and 
the medical device software guidelines and standards. Med-Trace may be used to 
diagnose an organization’s strengths and weaknesses in relation to their medical 
device software development traceability practices.  
 
 
Figure 1. Stages in a Med-Trace Assessment 
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X.3.1 Med-Trace Stages  
Med-Trace is composed of eight stages (see figure 1). The assessment team typi-
cally consists of two assessors who conduct the assessment between them. It is es-
sential that the assessors are trained in how to conduct a Med-Trace assessment 
and have the requisite knowledge of the requirements for medical device software 
traceability. 
The purpose of stage 1 of a Med-Trace assessment is to “Receive Site Briefing 
and Develop Assessment Schedule”. This involves a preliminary meeting between 
the assessment team and the organization wishing to undergo a Med-Trace as-
sessment. The assessment team discuss the main drivers for the organization em-
barking upon a Med-Trace assessment and what can be achieved. Based on the 
outcome of that discussion an assessment schedule is prepared and agree.   
The purpose of stage 2 is to “Conduct Overview Briefing” During this stage the 
lead assessor provides an overview of the Med-Trace assessment to members of 
the organization who will be involved in the subsequent stages of the assessment. 
This includes what the assessment will involve and cover.  What will be required 
and expected of the participants will also be outlined. 
The purpose of stage 3 is to ”Analyse Key Documents”.  The objective of this 
stage is to provide insight into relevant process documentation and artefacts which 
refer or relate to traceability.  These are collected, analysed and discussed by the 
assessors and they record their findings. The first 3 stages are normally performed 
on the organization’s premises, but the documentation collected in stage 3 is 
sometimes taken off-site as it can then be used to assist with the generation of ad-
ditional questions for stage 4.  
The primary source of data for a Med-Trace assessment is gathered through a 
series of interviews conducted in stage 4.  Therefore the purpose of stage 4 is to 
“Conduct Interviews”.  At this stage  a set of scripted questions (Appendix A) are 
used as the foundation for asking questions that are based upon the software trace-
ability literature search, traceability practices within the CMMI
®
 and ISO/IEC 
15504-5 models, and traceability practices that are required by the medical device 
industry. References are provided in Appendix A to show the sources of these 
questions.  The assessment team return onsite and key staff members from the or-
ganization are interviewed. Each interview is scheduled to last approximately 1.5 
hours. At each interview two assessors and one or more representatives from the 
organization are present. The lead assessor conducts the interview based on the 
scripted questions and evaluates the responses. The second assessor prepares in-
terview notes based on the responses and may ask additional questions if clarifica-
tion is required on specific points.  
The purpose of stage 5 is to “Generate Assessment Results and Create the Find-
ings Report”.  This is a collaborative exercise between the assessors to develop the 
findings report and takes place off-site.  The evaluation and interview notes are 
analysed and discussed in detail from each interview.  The findings from all the 
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interviews and from the results from document analysis (undertaken at stage 3) are 
then considered and the assessment results generated.  Based on these results the 
findings report is prepared and finalised. The resultant findings report consists of a 
list of strengths, issues and suggested actions for improving traceability. 
The purpose of stage 6 is to “Deliver the Findings Report”.  This stage takes 
place on-site and involves the lead assessor presenting the findings report to man-
agement and participating staff in the organization. Stage 7’s purpose is to “De-
velop a Traceability Improvement Plan with the Organization”. This involves the 
assessors collaborating with management and staff from the organization to col-
lectively develop a pathway towards achieving highly effective and regulatory 
compliant traceability practices. The findings report provides guidance to the as-
sessed organization and will focus upon practices that will provide the greatest 
benefit in terms of the organizations business goals with regard to traceability, in 
addition to quality and compliance.  The collaborative aspect of this step is essen-
tial as the relevant management and staff take a key part in developing the im-
provement plan and they ultimately have ownership of it. In these circumstances 
they are motivated to ensure its successful implementation.  
The purpose of stage 8 is to “Re-assess the Traceability Improvement Plan and 
Produce a Final Report”. As part of this stage the assessed organization is revisited 
approximately 3 months after the completion of stage 7. Progress is reviewed 
against the recommended improvement path. The outcome of this stage is an up-
dated improvement path and a final report detailing the progress that has been ac-
complished along with additional recommendations.  
X.4. Implementation of Med-Trace  
In this section we discuss how we implemented the Med-Trace assessment method 
in two medical device organizations.  The objective of performing both case stud-
ies was to demonstrate how Med-Trace could be used within similar sized and 
types of organizations (albeit in different countries) to assess the current status of 
their software traceability processes. We felt that it was important to illustrate the 
findings from implementing Med-Trace in more than one organization so observa-
tions could be made in relation to both the findings and the performance of Med-
Trace. Additionally, we wanted to discover what the main issues are that medical 
device software development organizations face in terms of traceability. We pre-
sent the process improvement objectives that were collaboratively agreed by both 
organizations to improve their respective traceability process.  We also outline our 
observations from the findings of undertaking both assessments. 
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X.4.1 Implementation in MedSoft  
We implemented a Med-Trace assessment in a Small to Medium Size (SME) Irish 
medical device organization, MedSoft (a pseudonym). MedSoft develop electronic 
based medical devices that require compliance with both the FDA and the MDD.  
MedSoft sought a resource-light method to obtain guidance as to how they could 
improve their software development traceability process, which Med-Trace pro-
vided. 
X4.1.1 Med-Trace Assessment Recommendations Provided to MedSoft  
Based on the analysis of the results from the Med-Trace assessment, and in col-
laboration with MedSoft staff, an improvement plan was developed with the fol-
lowing recommendations: 
 
1. The organization will initiate steps to measure the time spent on trace-
ability and evaluate its effectiveness.    
2. The task of performing traceability, in future, will be identified as part of 
the project plan and adequate time will be allocated to undertake this im-
portant task.   
3. Good practices which are employed while performing the traceability 
process will be documented in an efficient format and disseminated to 
relevant parties as and when required.  
4. Project managers will mandate the use of traceability while conducting 
impact analysis, promoting its usage as a management tool and thus ena-
bling the capture of information for management use. 
5. The software development lifecycle will contain milestones which will 
not permit further advancement to other phases/stages of the lifecycle un-
til the requirements for traceability are satisfied.  
6. A mechanism for tracing the open bugs/known issues to the 
safety/hazard/risk management system and linking them to the require-
ments will be made available and utilised.  
7. The organization will evaluate tools for the process of automating trace-
ability and requirements management. A tool will then be selected and 
implemented.  
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X.4.2 Implementation in MedNorth  
We also undertook a Med-Trace assessment in a UK based medical device organi-
zation, MedNorth (a pseudonym). Like MedSoft, MedNorth is an SME and de-
velop electronic-based medical devices that require compliance with both the FDA 
and the MDD. MedNorth also sought a resource-light method to obtain guidance 
as to how they could improve their software development traceability process.  
X4.2.1 Med-Trace Assessment Recommendations provided to MedNorth  
Based on the analysis of the results from the Med-Trace assessment (the Med-
North response to one of the Med-Trace scripted questions is illustrated in Table 
1), and in collaboration with MedNorth staff, a pathway was developed as follows: 
1. The process for software development traceability and for meetings be-
tween the various parties involved will be formalised and documented. 
2. A formal training program will be introduced to ensure the adoption of 
best traceability practices for requirements and risk management.  
3. The current Excel-based traceability application will be replaced with an 
appropriate automated traceability tool.  
4. Terminology usage with regard to traceability will be standardised and a 
formal definition of both risk and hazard agreed. A formal method for 
quantifying probability of harm will also be introduced and deployed. 
5. A defined traceability and validation procedure will be developed, im-
plemented and monitored to verify the activities of the staff that perform 
the traceability and validation function. 
6. A formal procedure will be developed and implemented to facilitate 
mapping from the design documentation to the software code.     
7. Resources will be allocated to enable the full implementation of the 
Ideagen tool.  This tool has already been purchased to allow digital signa-
tures to be recorded at each development stage, but it had not been prop-
erly implemented in the organization. 
 
Table 1 –  MedNorth response to a Med-Trace scripted question 
Question   
Response  
What kind of resources are 
provided for the activity of 
traceability management?  
MedNorth developed a dedicated process specifically for 
traceability that provides coverage of hardware and soft-
ware. Part of this process involves meetings between par-
ties that are involved in the development of various com-
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ponents that must work together in order to produce the 
final medical device product. MedNorth feel that the in-
clusion of these meetings as part of their traceability pro-
cedure is a good way of bringing everyone together from 
the different areas (i.e. software, hardware, mechanical) 
to ensure that everyone is fully aware of what is required 
from them and to help ensure that nothing slips within the 
overall project.  
The project manager in MedNorth has overall owner-
ship of traceability.  
X.4.3 Observations from the 2 Med-Trace Implementations 
In both organizations the importance traceability plays in medical device software 
development was understood and a member of the management team was respon-
sible for its implementation.  The dual role of tracing requirements and managing 
risk and hazards were appreciated, but were recognized as complex and difficult to 
achieve. The lack of detailed guidance on how best to implement traceability was 
highlighted as a problem by both organizations. While they both employed a proc-
ess for software development with regard to traceability this needed to be im-
proved and formalized.  The requirement for relevant training and the ability to re-
cord and leverage best practice with regard to traceability also emerged.   
The serious limitations of utilising manual tools such as Excel, to manage 
traceability and the need for automated tools was recognized, and required ad-
dressing. It was also appreciated that this had to be undertaken with due care and 
within the financial and temporal constraints of both organizations. 
Both organizations welcomed the opportunity to participate in a Med-Trace as-
sessment.   The fact that it was lightweight and specifically addressed traceability 
was considered worthwhile and very relevant.  The findings reports addressed key 
areas where improvements were required and this was confirmed in consultation 
with the management and staff of both organizations.  The adoption of the devel-
opment pathway provided realistic goals and the collaborative process provided 
motivation for their achievement.  Both organizations are implementing their re-
spective development pathways and have agreed to be reassessed (part of stage 8 
of the Med-Trace assessment method). 
X.5 Medical Device Software industry Traceability Challenges   
Due to the critical nature of medical device software and the potential harm failure 
can cause, the implementation of an effective traceability process is essential. 
15 
Therefore, to ensure validity, software requirements traceability analysis needs to 
be conducted to trace software requirements to (and from) system requirements, 
and to risk analysis results. While this is mandated by the medical device guide-
lines it is recognized by the industry as a difficult and complex endeavour. This is 
not helped by the fact that organizations have highlighted the lack of detailed 
guidance and direction as to how this can be successfully achieved. 
 A key factor which has been highlighted by the Med-Trace assessments and 
the literature is the importance of incorporating automated traceability tools into 
the development process. Especially, considering that many medical device soft-
ware development organizations employ manual systems like Excel for traceabil-
ity [44]. This is a real challenge, which needs to be addressed. There is also a re-
quirement to define and formalise processes which specifically facilitate effective 
traceability. These need to be supported by resources to provide relevant training 
and infrastructure.   
While the need to provide requirements traceability cannot be underestimated, 
the necessity to provide traceability for each identified hazard is of equal impor-
tance.  Risk management is a key activity for medical device software develop-
ment and hazards have to be traced to risk analysis, risk evaluation and the im-
plementation and verification of the risk control measures.  
The number of standards and guidelines which govern medical device software 
development is also a challenge.  To determine the exact requirements of each 
document with regard to traceability can be time consuming. The information pro-
vided can also lack the level of detail required to successfully implement these re-
quirements.  
When comparing generic and medical device software development the key 
difference lies in the mission critical nature and potential for harm which can be 
inherent in medical device software. Therefore, as risk is a key factor, require-
ments and hazard traceability both need to be addressed.  It is somewhat surprising 
in these circumstances that tools are used less in medical device software devel-
opment than in other software development domains [44]. However, upon closer 
inspection of the medical device standards there is perhaps a reason in that such 
tools will also have to be validated in order to achieve regulatory compliance. The 
use of new automated tools require validation (including Risk and Hazard Analy-
sis/Management) in their own right prior to their use as part of the Quality Man-
agement System. This is a very time consuming and costly exercise, especially for 
a SME. The more complex the tool, the more time, effort, cost associated with the 
validation and roll-out of the tool. 
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X.6 Foundation for Further Research in this Area 
The work presented here will be used as the basis for further research in the area 
of medical device software traceability.  It will also be utilized in Medi SPICE  
[5], [42]  a software process assessment and improvement model specifically for 
the medical device industry.  The Regulated Software Research Group is currently 
developing Medi SPICE in collaboration with international standards bodies and 
the medical device industry. 
Med-Trace will continue to be refined based on the results of ongoing research 
and feedback from future assessments and practitioners. The goal is to roll out 
Med-Trace nationally and internationally to assist with traceability. Given the 
positive response it has received, it is envisaged that research will be undertaken 
into the development of a tool to automate Med-Trace.  The objective of the tool 
will be to facilitate the international roll out of Med-Trace and encourage its wider 
use. It is planned that the tool will also collect metrics which will be automatically 
passed back to the Regulated Software Research Group for analysis. This will as-
sist with the future development of Med-Trace and Medi SPICE. 
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Appendix A - Sample Scripted Med-Trace Questions 
 








What kind of resources are provided for the activity of trace-
ability management?  
[45]*  
Is there a documented procedure in place for traceability? Is 
training provided on traceability and to what extent is explicit 
knowledge made available on software traceability  
[45]*  
Implementation of traceability - Forward, Backward Traceabil-
ity and the Relationship between Requirements (Dependent 
Requirements), Traceability tracking from safety the perspec-
tive and traceability to hazards/risk management. 
[46]*  
Where does traceability start - market requirements, product 
roadmap, system specifications? Where does proper require-
ment tagging start and how is it documented? Does any tool 
support this? How is safety classification in traceability 
achieved? 
  
How is traceability established between System Requirements, 
Software Requirements, and Software System testing?  
Section  5.1.1 
[10]*  
How are software requirements traceable to system require-  Section 5.2.6 
20  
ments and how is this verified? [10]* 
How is traceability demonstrated between the software re-
quirements and software system testing?  
Section 5.7.4 
[10]* 




What traceability activities are undertaken during the coding 
and construction phase?  
Section 5.2.4 
[6]* 
How are software systems test procedures traced to software 
and verified? What elements of system test procedures need to 
be traced? What are the difficulties in tracing? How does up-




How are risk control measures traced to the software require-
ments?  
Section 7.3.3  
[10]* 
How is traceability established between the risk control meas-
ures implemented in software?  
Section  6.3 
[16]* 
The standard IEC 62304 specifies that the manufacturer shall 
document traceability of software hazards as appropriate:  
How is such complex traceability achieved? What are the tools 





How is traceability undertaken from the software related haz-
ards and the software risk control measures to the correspond-
ing safety-related software requirements and the software items 





How is software requirements traceability analysis conducted 
to trace software requirements to (and from) system require-
ments to risk analysis results?  
Section 5.2.2 
[6]* 
What documentation do you use to provide traceability to link 
together design, implementation, testing, and risk management?  
[7]* 
 
In a software release, there is usually a process of noting down 
the known errors/known bugs. Is there a concept of traceability 
from these known bugs to the requirements or any other techni-
cal documentation?  




How is the process of traceability measured and managed for 
effectiveness? Is there a way of consolidating feedback peri-
odically on how well this process is performed?  
[45]*  
To what extent has the organization automated traceability? 
What kind of tools are available which you think are useful for 





* Denotes the relevant reference from the Software Traceability Literature or 
Medical Device Standards & Guidelines on which the question is based 
